Seres grabs $20M on PhIII microbiome launch; Gilead submits NDA; Alkermes begins Phase IIIb study
→ Seres $MCRB is taking another step forward in its comeback effort on a microbiome drug that rattled everyone in the field when it failed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
